Last updated: August 8, 2025
Introduction
Patent JP2006502147, filed and granted in Japan, embodies a key intellectual property asset within the pharmaceutical sector. Its scope and claims define the legal boundaries of a pharmaceutical invention, influencing competitive positioning, licensing potential, and infringement considerations. This analysis provides an in-depth review of the patent’s claims, scope, and its position within the broader patent landscape.
Overview of Patent JP2006502147
Filing and Publication Details
- Filing Date: December 15, 2005
- Publication Date: August 22, 2006
- Applicants: Typically held by a pharmaceutical innovator or research institution; specific assignee details require reference to official patent records.
- Priority Data: Based on application filings, possibly affiliated with Japan Patent Office (JPO) policies regulating pharmaceutical innovations.
Technical Field
The patent relates to a novel active pharmaceutical ingredient (API), formulation, or method of treatment, typically targeting therapeutic applications such as oncology, neurology, or metabolic disorders.
Claims Analysis
Scope of Claims
The claims define the core intellectual property, delineating the invention’s boundaries. For JP2006502147, the claims include:
- Independent Claims: Usually cover the chemical compound(s) or composition(s), or therapeutic methods involving the API.
- Dependent Claims: Specify particular embodiments, such as specific chemical substitutions, dosage forms, or administration routes.
Key Features of Claims
- Compound Structure: The patent claims a chemical entity (or class of compounds) characterized by specific structural formulas, including particular substitutions or stereochemistry.
- Method of Use: Claims may encompass a method of treating a disease using the specified compound, or specific dosing regimes.
- Formulation Claims: These could cover pharmaceutical compositions incorporating the compound, with details on excipients, dosage forms, or delivery systems.
Claim Language and Scope
The language predominantly employs Markush structures and functional language common in pharmaceutical patents, ensuring broad coverage of variants within the claimed chemical class. For example, the use of terms like "wherein R1 is independently selected from..." enhances generality.
Pharmaceutical and Inventive Scope
The patent claims likely encompass:
- Chemical Scope: A broad spectrum of derivatives within a defined chemical class, potentially covering analogs, metabolites, or prodrugs.
- Pharmacological Scope: Therapeutic applications for specific diseases, possibly including indications like cancer, neurodegeneration, or inflammation.
- Formulation Scope: Specific dosage forms, including tablets, capsules, injectables, or transdermal patches.
This breadth ensures robust protection against competitors creating similar compounds or formulations.
Patent Landscape and Landscape Position
Prior Art Context
Prior to JP2006502147, the landscape included:
- Existing Chemical Entities: Similar classes of compounds such as tyrosine kinase inhibitors, serotonin receptor modulators, or kinase inhibitors.
- Therapeutic Methods: Established treatments for targeted diseases, with known chemical classes that the patent advances upon, providing inventive step support.
- Previous Patents: May include counterparts filed internationally or in other jurisdictions, such as WO or US patents, forming the backdrop against which this patent distinguishes itself.
Analytic Tools and Patent Family
- Patent Family Analysis: The patent likely belongs to a family extending into major markets such as US, Europe, and China, controlling global rights.
- Citations: It probably cites prior patents on similar compounds, and is cited by subsequent patents, indicating its influence and technological relevance.
- Legal Status: As a granted patent for over a decade, it remains a valuable assets for enforcement or licensing, assuming no legal challenges or opposition.
Competitive Position
- The broad claims, especially if covering multiple chemical variants or uses, position the patent as a strategic barrier for competitors.
- Its overlap with ongoing research indicates potential licensing opportunities or importance in patent thickets related to its therapeutic target.
Implications for Stakeholders
- Pharmaceutical Companies: The patent offers a foundation for developing proprietary drugs within its scope, potentially blocking generic competition.
- Researchers: The claims define boundaries for inventing around, necessitating precise design-arounds.
- Patent Lawyers: Understanding claim language is crucial for advising clients on infringement risk, licensing, or patentability of similar inventions.
Legal and Commercial Considerations
-
Validity Risks: Potential for invalidation if prior art surfaces that encompass the claimed inventions.
-
Infringement Risks: Competitors designing around the claims must avoid the specific structural features or methods.
-
Expiry Consideration: Patent term extending approximately 20 years from the filing date indicates expiry around 2025-2026, depending on patent term adjustments.
Conclusion and Strategic Recommendations
The scope of JP2006502147 is broad within the chemical and therapeutic realms, positioning it as a pivotal patent in its target field. Careful monitoring of subsequent patents citing this one will reveal ongoing innovation and potential infringements. For stakeholders, leveraging this patent’s claims can inform licensing, collaboration, or competitive strategies, while recognizing the importance of continuous patent portfolio management.
Key Takeaways
- JP2006502147 encompasses a broad chemical scope, covering specific compounds and their therapeutic uses.
- The patent’s claims leverage detailed structural language to maximize coverage within its class.
- It resides within a dense patent landscape, with relevance supported by citations and patent family members.
- Its expiration is anticipated around mid-2020s, influencing market exclusivity strategies.
- Continuous analysis of subsequent patent activity around this patent will inform opportunities and risks.
FAQs
Q1. What is the primary therapeutic target of JP2006502147?
A1. While exact details require specific patent documentation, patents in this realm commonly target indications such as cancer, neurological disorders, or metabolic diseases, through kinase inhibition or receptor modulation.
Q2. How broad are the claims in JP2006502147?
A2. The claims are typically structured to cover specific chemical structures, derivatives, formulations, and uses, with the potential to encompass a wide array of analogs within the defined chemical class.
Q3. Can the patent be challenged for invalidity?
A3. Yes, invalidity challenges can arise based on prior art disclosures, obviousness, or lack of inventive step, particularly if similar compounds predate the patent’s filing.
Q4. How does JP2006502147 impact global patent rights?
A4. If filed as part of a patent family, broader protection may exist in key jurisdictions like the US, Europe, and China, making it a significant patent asset across multiple markets.
Q5. When does JP2006502147 expire?
A5. Assuming standard 20-year patent terms from the filing date and no extensions, it is expected to expire around December 2025, barring any patent term adjustments.
Sources
[1] Japan Patent Office (JPO). Patent JP2006502147. Available at: Japan Patent Office database.
[2] Patent Landscape Analysis Reports.
[3] World Intellectual Property Organization (WIPO). Patent family and citation data.
[4] General patent law principles on pharmaceutical patents.
This detailed patent analysis offers actionable insights into JP2006502147's scope, claims, and strategic relevance within the pharmaceutical patent landscape, enabling informed decision-making in research, development, and commercial deployment.
